Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 17/20 | 0.79 |
| ▸ | MMP2 | P08253 | 8/20 | 0.79 |
| ▸ | MMP13 | P45452 | 13/20 | 0.61 |
| ▸ | MMP8 | P22894 | 4/20 | 0.61 |
| ▸ | MMP1 | P03956 | 8/20 | 0.59 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.59 |
| ▸ | MMP3 | P08254 | 1/20 | 0.57 |
| ▸ | BMP1 | P13497 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13639276 | 1.00 | MMP9 (0.79) | MMP9MMP2MMP13MMP8MMP1 | |
| SCHEMBL26770089 | 0.92 | MMP9 (0.79) | MMP9MMP2MMP13MMP8MMP1 | |
| SCHEMBL9168780 | 0.92 | MMP9 (0.79) | MMP9MMP2MMP13MMP8MMP1 | |
| Hydrochloric Acid SCHEMBL7347781 | 0.91 | MMP9 (0.78) | MMP9MMP2MMP13MMP8MMP1 | |
| SCHEMBL13640701 | 0.91 | MMP9 (0.69) | MMP9MMP2MMP13MMP8MMP1 | |
| SCHEMBL13639279 | 0.91 | MMP9 (0.69) | MMP9MMP2MMP13MMP8MMP1 | |
| SCHEMBL26770039 | 0.90 | MMP9 (0.77) | MMP9MMP2MMP13MMP8MMP1 | |
| SCHEMBL13639256 | 0.90 | MMP9 (0.80) | MMP9MMP2MMP13MMP8MMP1 | |
| SCHEMBL13639194 | 0.90 | MMP9 (0.80) | MMP9MMP2MMP13MMP8MMP1 | |
| SCHEMBL13570600 | 0.90 | MMP9 (0.80) | MMP9MMP2MMP13MMP8MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357139-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | Artizan Biosciences, Inc. | 2023-11-09 | — | — | US | disclosed |
| US-20120282180-A1 | Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120282180-A1 | Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2012-11-08 | — | — | US | disclosed |
| EP-2520573-A1 | Compounds with matrix-metalloproteinase inhibitory activity | Westfälische Wilhelms-Universität Münster (DE) | 2012-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282180-A1 | Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof | MMP1, MMP17, MMP25 | MMP9 4/4885MMP2 16/4885MMP13 17/4885 |
| US-20230357139-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | FABP2, APC, SI | MMP9 612/4885MMP2 166/4885MMP13 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.